Skip to main content
EJNMMI Research
Figure 5 | EJNMMI Research

Figure 5

From: The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®

Figure 5

Combination of PARPi with chemotherapy increases tumour growth delay, DNA damage, tumour cell death, and tumour uptake of DAB4 in vivo . LL2 tumour-bearing mice were administered PARPi alone or with chemotherapy (chemo). (A) Percentage change in tumour volume after treatment (B) Kaplan-Meier survival analysis. * p < 0.05 compared to untreated or chemotherapy alone, n = 4 to 5. Tumour sections were examined for (C) γ-H2AX, (D) cell death (ApopTag+) and (E) DAB4 binding. * p < 0.05, ** p < 0.01, *** p <0.001, n = 3. (F) Shows (i) DAPI-counterstained tumour section with detection of (ii) cell death (ApopTag+), and (iii) biotinylated DAB4 with merged images shown in (iv; yellow = co-localisation of DAB4 with dead cells). Bar = 50 μm.

Back to article page